Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to KRASG12C Inhibitors
Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall, et al.
Cancers (2021) Vol. 13, Iss. 1, pp. 151-151
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 2, pp. 120-131
Open Access | Times Cited: 591
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 251
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches
Martin Reck, David P. Carbone, Marina Chiara Garassino, et al.
Annals of Oncology (2021) Vol. 32, Iss. 9, pp. 1101-1110
Open Access | Times Cited: 220
Targeting mutations in cancer
Michael R. Waarts, Aaron J. Stonestrom, Young C. Park, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 8
Open Access | Times Cited: 145
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 132
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Albert K. Kwan, Gary A. Piazza, Adam B. Keeton, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 131
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Martha Dillon, Antonio R. Lopez, Edward H. Lin, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5059-5059
Open Access | Times Cited: 107
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 90
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 70
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 46
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
Niamh Coleman, Lingzhi Hong, J. Zhang, et al.
ESMO Open (2021) Vol. 6, Iss. 6, pp. 100319-100319
Open Access | Times Cited: 84
The Importance of Being PI3K in the RAS Signaling Network
Cristina Cuesta, Cristina Arévalo-Alameda, Esther Castellano
Genes (2021) Vol. 12, Iss. 7, pp. 1094-1094
Open Access | Times Cited: 68
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 63
Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy
Abdul Rashid Issahaku, Namutula Mukelabai, Clement Agoni, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 63
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
Atish Mohanty, Arin Nam, Saumya Srivastava, et al.
Science Advances (2023) Vol. 9, Iss. 41
Open Access | Times Cited: 33
New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine
Nana Wang, Haibo Mei, Gagan Dhawan, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3651-3651
Open Access | Times Cited: 29
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 11
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C
Caressa Lietman, Melissa L. Johnson, Frank McCormick, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 205-217
Open Access | Times Cited: 32
Structural basis for SHOC2 modulation of RAS signalling
Nicholas P. D. Liau, Matthew C. Johnson, Saeed Izadi, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 400-407
Open Access | Times Cited: 30
Targeting KRAS in Non-Small Cell Lung Cancer
E. Corral de la Fuente, M.E. Olmedo García, Ana Gómez Rueda, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 29
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Cen Liu, Danyang Ye, Hongliu Yang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 18
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten, Mariano Barbacid
Molecular Oncology (2021) Vol. 16, Iss. 5, pp. 1057-1071
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top